多发性骨髓瘤(multiple myeloma, MM)是一种恶性浆细胞疾病,免疫治疗为MM患者带来里程碑式的进步,其中靶向B细胞成熟抗原(B-cell maturation antigen,BCMA)的双特异性T细胞接合器(bispecific T cell engager,BiTE)是复发难治MM(relapse and refractory multiple myeloma, RRMM)重要、极具前景的治疗手段之一[1]。. This evidence concerns the gene TNFRSF17 and AL amyloidosis.